STOCK TITAN

HYPERFINE Stock Price, News & Analysis

HYPR Nasdaq

Welcome to our dedicated page for HYPERFINE news (Ticker: HYPR), a resource for investors and traders seeking the latest updates and insights on HYPERFINE stock.

Hyperfine Inc (HYPR) pioneers accessible MRI technology through its groundbreaking Swoop® Portable MR Imaging System, transforming diagnostic capabilities in critical care and underserved settings. This page serves as the definitive source for verified news and announcements related to corporate developments, clinical milestones, and financial performance.

Investors and healthcare professionals will find timely updates on regulatory clearances, partnership agreements, quarterly earnings, and technological advancements. Our curated collection includes press releases about device deployments, peer-reviewed study results, and strategic initiatives driving portable MRI adoption.

Key coverage areas include Swoop system innovations, financial results analysis, leadership updates, and market expansion efforts. All content is rigorously verified to ensure accuracy and relevance for stakeholders evaluating HYPR's position in the medical imaging sector.

Bookmark this page for streamlined access to Hyperfine's latest progress in redefining bedside diagnostics through ultra-low-field MRI technology. Check regularly for objective reporting on developments impacting both clinical practice and long-term corporate strategy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.15%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.76%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.1%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Hyperfine, Inc. (NASDAQ: HYPR), pioneer of the Swoop® system, the first FDA-cleared portable MRI system, announced it will report its Q1 2023 financial results on May 11, 2023. The company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. Swoop® provides neuroimaging at the point of care, offering bedside imaging capabilities where traditional MRI access is limited or unavailable. Initially cleared by the FDA in 2020, it is now also approved in Canada, Australia, and other regions, enhancing patient care through accessible diagnostic imaging. Interested investors can access the live audio webcast via the company’s website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.29%
Tags
Rhea-AI Summary

Hyperfine, Inc. (Nasdaq: HYPR) reported fourth quarter and full year 2022 financial results, achieving revenue of $6.8 million for the year, up from $1.5 million in 2021. In Q4 2022, revenue was $1.424 million, compared to $0.436 million in Q4 2021. The net loss for the year was $73.164 million, or $1.04 per share, an increase from $64.851 million or $17.57 per share in the previous year. The company ended the year with $117.472 million in cash. 2023 guidance estimates revenue between $10 to $14 million with a cash burn of $40 to $45 million. Significant achievements included FDA clearances and the installation of 35 commercial systems.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.68%
Tags
-
Rhea-AI Summary

Hyperfine, Inc. (Nasdaq: HYPR), creator of the first FDA-cleared portable MRI system, Swoop®, announced it will report financial results for Q4 and full year 2022 on March 21, 2023. The management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET, accessible through their investor page. The Swoop® system, approved for brain imaging in multiple countries, aims to enhance patient care through accessible diagnostic imaging. Since its FDA clearance in 2020, it has revolutionized neuroimaging by bringing bedside MRI capabilities to clinicians, improving diagnosis where conventional MRI is not feasible.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.68%
Tags
-
Rhea-AI Summary

Hyperfine, Inc. (Nasdaq: HYPR) announced FDA 510(k) clearance for an updated version of its Swoop® Portable MR Imaging® system software, enhancing clinical utility in neurocritical care. The new software improves diffusion-weighted imaging (DWI) with a 42% increase in signal-to-noise ratio, essential for diagnosing neurological conditions. This update aims to provide clearer images and better patient care in diagnosing and monitoring stroke progression. The improved software is expected to roll out to customers in March 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.83%
Tags
none
Rhea-AI Summary

Hyperfine, Inc. (Nasdaq: HYPR) has achieved CE Marking for its portable MRI system with AI-powered imaging software, confirming compliance with EU safety standards. This milestone allows the company to explore future commercial opportunities within the European Economic Area (EEA) while maintaining its focus on the U.S. market in 2023. Compliance with the EU's Medical Device Regulation (MDR) was essential for legal marketing in Europe, reflecting an increase in regulatory rigor. CEO Maria Sainz emphasized the achievement's significance in enhancing the company's market potential.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.22%
Tags
none

FAQ

What is the current stock price of HYPERFINE (HYPR)?

The current stock price of HYPERFINE (HYPR) is $0.8 as of July 3, 2025.

What is the market cap of HYPERFINE (HYPR)?

The market cap of HYPERFINE (HYPR) is approximately 56.9M.
HYPERFINE

Nasdaq:HYPR

HYPR Rankings

HYPR Stock Data

56.92M
58.84M
8.7%
22%
2.61%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
GUILFORD